Dihydroartemisinin and Piperaquine could become a major weapon against malaria

Potential to make a major impact in the lives of people at risk of malaria

03 Oct 2005

This statement by Prof. Nick White was made during the 2nd COST B 22 Congress on “Drug Discovery & Development for Parasitic Diseases” which took place from 29 September-1 October 2005. Prof. White also noted, “We hope the large Phase III trial currently underway will confirm that it is well tolerated and effective, and also easy to use and well tolerated. With the easy once-a-day regimen for three days and the low cost, it could potentially have widespread use and save many lives.”

“The COST B22 Congress is a very important meeting addressing diseases representing major medical and social challenges,” said Dr. Paolo Carminati, Director of R&D of the sigma-tau Group. “We are grateful to the University of Siena for hosting the event and showing keen interest in malaria and our efforts to combat the disease.”

“We are particularly proud to have Eurartekin® being discussed in such important international setting,” said Dr. David Ubben, director of clinical development at MMV, “If successful, this antimalarial drug will be one of the few drugs in history designed and developed primarily for a disease of the poor. It has the potential to make a major impact in the lives of people at risk of malaria.”